In a result eagerly awaited by Wall Street, drug developer Seattle Genetics announced that its experimental cancer medicine shrank tumors in 75% of patients with Hodgkin lymphoma that had relapsed despite rounds of chemotherapy and bone marrow transplants.

FORBES: Seattle Genetics Scores Win For Smart-Bomb Cancer Drugs

Now an experimental drug from Iceland's DeCode Genetics shows promise of quelling heart inflammation in a preliminary human trial.

FORBES